Literature DB >> 8237699

MR of intraparotid masses.

B N Schlakman1, D M Yousem.   

Abstract

PURPOSE: To determine which MR techniques are best for identifying intraparotid masses and to assess the utility of MR for predicting specific diagnosis.
METHODS: A retrospective review of 31 intraparotid masses was performed. Lesion conspicuity and signal intensity characteristics were evaluated by objectively measured regions of interest and by subjective visual review.
RESULTS: The T1-weighted images produced the highest lesion conspicuity in 25 of 31 masses. All the masses were easily detected as hypointense lesions on the T1-weighted scans with good or excellent conspicuity; on the T2-weighted images nine lesions appeared isointense to the normal parotid tissue, including six malignancies. Gadolinium-enhanced images were not helpful for identifying the intraparotid masses. Warthin tumors and malignancies tended to be hypointense or low in conspicuity on T2-weighted images.
CONCLUSIONS: The T1-weighted images were best for detecting parotid masses. The T2-weighted images may help in limiting a differential diagnosis, but a specific diagnosis cannot be made without biopsy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8237699      PMCID: PMC8332748     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  9 in total

1.  Different imaging techniques in the head and neck: Assets and drawbacks.

Authors:  Thomas J Vogl; Marc Harth; Petra Siebenhandl
Journal:  World J Radiol       Date:  2010-06-28

2.  MR imaging of parotid tumors: typical lesion characteristics in MR imaging improve discrimination between benign and malignant disease.

Authors:  A Christe; C Waldherr; R Hallett; P Zbaeren; H Thoeny
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-30       Impact factor: 3.825

3.  Retrospective review: usefulness of a number of imaging modalities including CT, MRI, technetium-99m pertechnetate scintigraphy, gallium-67 scintigraphy and F-18-FDG PET in the differentiation of benign from malignant parotid masses.

Authors:  Nozomi Ozawa; Terue Okamura; Koichi Koyama; Keiko Nakayama; Joji Kawabe; Susumu Shiomi; Hideo Yamane; Yuichi Inoue
Journal:  Radiat Med       Date:  2006-01

4.  Warthin tumor of the parotid gland: diagnostic value of MR imaging with histopathologic correlation.

Authors:  Mitsuaki Ikeda; Ken Motoori; Toyoyuki Hanazawa; Yuichiro Nagai; Seiji Yamamoto; Takuya Ueda; Hiroyuki Funatsu; Hisao Ito
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

5.  Preoperative diagnostic values of fine-needle cytology and MRI in parotid gland tumors.

Authors:  J Paris; F Facon; T Pascal; M A Chrestian; G Moulin; M Zanaret
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-01-15       Impact factor: 2.503

Review 6.  Parotid tumors: MR imaging with pathological correlation.

Authors:  Mika Okahara; Hiro Kiyosue; Yuko Hori; Akira Matsumoto; Hiromu Mori; Shigeo Yokoyama
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

7.  Dynamic Contrast Magnetic Resonance Imaging (DCE-MRI) and Diffusion Weighted MR Imaging (DWI) for Differentiation between Benign and Malignant Salivary Gland Tumors.

Authors:  S Assili; A Fathi Kazerooni; L Aghaghazvini; H R Saligheh Rad; J Pirayesh Islamian
Journal:  J Biomed Phys Eng       Date:  2015-12-01

8.  Tumor blood flow and apparent diffusion coefficient histogram analysis for differentiating malignant salivary tumors from pleomorphic adenomas and Warthin's tumors.

Authors:  Fumine Tanaka; Maki Umino; Masayuki Maeda; Ryohei Nakayama; Katsuhiro Inoue; Ryota Kogue; Makoto Obara; Hajime Sakuma
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.996

9.  Two-phase helical computed tomography study of salivary gland warthin tumors: a radiologic findings and surgical applications.

Authors:  Yeon Hee Joo; Jin Pyeong Kim; Jung Je Park; Seung Hoon Woo
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-08-01       Impact factor: 3.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.